DS-REQ-002
Data Requirements for Human Drugs Submission: Content of the Dossier
Current edition
Version 4.0 of August 3, 2025
Current edition
Version 4.0 of August 3, 2025
About this standard
Content of Modules 1 to 5 of the registration dossier for new chemical entities, biologicals, biosimilars and generic products.
Recognition by market
Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts
No market listing is published yet.
Testing requirements that cite it
Open the market page and its pathway pages for the full requirement, protocol and report content
Saudi Arabia
- Validation and verification of analytical procedures, and method transferAnalytical method validation · Not stated
- Dossier format: eCTD, language and authentication of documentsDossier format · Not stated
- Nitrosamine impurities: risk assessment in the registration dossierImpurities · Not stated
- Active substance data: certificate of suitability, drug master file or full dataSpecifications · Not stated
- Quality data for biotechnology products: cell banks, characterization and viral safetySpecifications · Not stated
- Reference standards and reference materialsSpecifications · Not stated
- Specifications, batch analysis data and certificates of analysis in the quality dossierSpecifications · Not stated
Related standards: FDA eCTD submission guidance, MDR 2017 Fourth Schedule, Appendix II and III, JP notification on electronic study data (2024), M4(R4), M4Q(R1), M4Q(R2), M4S(R2), M4E(R2), ACTD, CDSCO Guidance for Industry (Biologicals), COFEPRIS CTD guide v3.0, DS-G-003. See all standards.